Prestige Consumer Healthcare Faces Shareholder Probe Over Clear Eyes® Production Woes, 11% Stock Drop
PBH is trading near its 52-week low of $42.62 (12% above the low).
Summary
Shareholder rights firm Hagens Berman is investigating Prestige Consumer Healthcare Inc. (PBH) for potential securities law violations. The probe centers on whether the company adequately disclosed significant revenue declines and production problems with its Clear Eyes® brand and Pillar5 facility, which caused an 11% stock drop on May 14. This follows the company's May 13 fiscal 2026 results, which showed a 20.6% revenue decrease in the Eye & Ear Care segment. An investigation of this nature can lead to costly litigation and further pressure on the stock.
At the time of this announcement, PBH was trading at $47.60 on NYSE in the Trade & Services sector, with a market capitalization of approximately $2.2B. The 52-week trading range was $42.62 to $85.29. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: PR Newswire.